Cell Therapy Shows Remarkable Ability to Eradicate Cancer in Clinical Study
Investigators from Memorial Sloan Kettering Cancer Center have reported more encouraging news about one of the most exciting methods of cancer treatment today. The largest clinical study ever conducted to date of patients with advanced leukemia found that 88 percent achieved complete remissions after being treated with genetically modified versions of their own immune cells. The results were published today in Science Translational Medicine.
“These extraordinary results demonstrate that cell therapy is a powerful treatment for patients who have exhausted all conventional therapies,” said Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan Kettering and one of the study’s senior authors. “Our initial findings have held up in a larger cohort of patients, and we are already looking at new clinical studies to advance this novel therapeutic approach in fighting cancer.”
Adult B cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer that develops in B cells, is difficult to treat because the majority of patients relapse. Patients with relapsed B-ALL have few treatment options; only 30 percent respond to salvage chemotherapy. Without a successful bone marrow transplant, few have any hope of long-term survival.
In the current study, 16 patients with relapsed B-ALL were given an infusion of their own genetically modified immune cells, called T cells. The cells were “reeducated” to recognize and destroy cancer cells that contain the protein CD19. While the overall complete response rate for all patients was 88 percent, even those with detectable disease prior to treatment had a complete response rate of 78 percent, far exceeding the complete response rate of salvage chemotherapy alone.
Dennis J. Billy, C.Ss.R, of Wynnewood, Pennsylvania, was one of the first patients to receive this treatment more than two years ago. He was able to successfully undergo a bone marrow transplant and has been cancer-free and back at work teaching theology since 2011. Paolo Cavalli, a restaurant owner from Oxford, Connecticut, remains in complete remission eight months after receiving his personalized T cell treatment.
A History of Scientific Achievements for Cell-Based Therapies
Cell-based, targeted immunotherapy is a new approach to treating cancer that harnesses the body’s own immune system to attack and kill cancerous cells. Unlike with a common virus such as the flu, our immune system does not recognize cancer cells as foreign and is therefore at a disadvantage in eradicating the disease. For more than a decade, researchers at Memorial Sloan Kettering have been exploring ways to reengineer the body’s own T cells to recognize and attack cancer. In 2003, they were the first to report that T cells engineered to recognize the protein CD19, which is found on B cells, could be used to treat B cell cancers in mice.
“Memorial Sloan Kettering was the first center to report successful outcomes using this CD19-targeted approach in B-ALL patients,” said Renier Brentjens, MD, PhD, Director of Cellular Therapeutics at Memorial Sloan Kettering and one of the study’s senior authors. “It’s extremely gratifying to witness the astonishing results firsthand in my patients, having worked for more than a decade developing this technology from the ground up.”
In March 2013, the same team of researchers first reported the results of five patients with advanced B-ALL who were treated with cell therapy. Remarkably, all five patients achieved complete remissions.
Results Demonstrate Potential of New Therapy
In the current study, seven of the 16 patients (44 percent) were able to successfully undergo bone marrow transplantation — the standard of care and the only curative option for B-ALL patients — following treatment. Three patients were ineligible due to failure to achieve a complete remission, three were ineligible due to preexisting medical conditions, two declined, and one is still being evaluated for a potential bone marrow transplant. Historically, only 5 percent of patients with relapsed B-ALL have been able to transition to bone marrow transplantation.
The Latest on: Cell therapy
via Google News
The Latest on: Cell therapy
- Inflammation produced by bacterial infection 'alerts' the brain stem cellson November 27, 2020 at 4:24 am
The study, directed by Isabel Fariñas and published in the November digital edition of the journal Cell Stem Cell, reveals that the inflammation produced by a bacterial infection 'alerts' the brain ...
- Novel CAR T-cell therapy shows promising early results in children with neuroblastomaon November 25, 2020 at 6:33 pm
A novel CAR T-cell therapy developed by researchers at UCL and designed to target cancerous tumors, has shown promising early results in children with neuroblastoma, a rare form of childhood cancer.
- Man left paralyzed after motorcycle accident hopeful after stem cell therapyon November 25, 2020 at 2:07 pm
"It gives me some sort of hope that in my lifetime, I could walk again, I could regain function again, I could birth a child. And that's the biggest thing, is the hope," said Nathan Bird, who survived ...
- Autologous Cell Therapy Market 2020-2024- Featuring Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., Among Others | Industry Analysis, Market Trends ...on November 25, 2020 at 12:03 pm
Technavio has announced its latest market research report titled Global Autologous Cell Therapy Market 2020-2024 (Graphic: Business Wire) LONDON-- ( BUSINESS WIRE )--The autologous cell therapy market ...
- The global market for CAR T-cell therapy is predicted to grow at a CAGR of 44.79% over the forecast period 2020-2030on November 25, 2020 at 7:17 am
Reportlinker.com announces the release of the report "Global CAR T-Cell Therapy Market: Focus on Product, Mechanism, ...
- CAR T Cell Therapy Market 2020 Research, Growth Opportunities, Analysis and Forecasts Report 2025on November 25, 2020 at 5:31 am
Global CAR T Cell Therapy Market is anticipated to reach over USD 2.99 Billion by 2025 According to a new research published by Polaris Market Research. The CAR T therapy uses the patient's own immune ...
- Stem Cell Therapy Global Market Report 2020-30: Covid 19 Growth and Changeon November 24, 2020 at 10:29 am
Reportlinker.com announces the release of the report "Stem Cell Therapy Global Market Report 2020-30: Covid 19 Growth and ...
- World's first: Drug guides stem cells to desired location, improving their ability to healon November 24, 2020 at 10:11 am
Scientists have created a drug that can lure stem cells to damaged tissue and improve treatment efficacy -- a scientific first and major advance for the field of regenerative medicine.
- Global Stem Cell Therapy Market 2020: Market Growth, Trends, Revenue, Share and Demands Research Reporton November 22, 2020 at 7:53 pm
Global “ Stem Cell Therapy " Market 2024 Research Report provide in-depth study of the present state of the Industry. Initially, the report shows a basic overview of the industry including definitions ...
- Novartis signs $50 million deal for Mesoblast cell therapy for COVID, beyondon November 20, 2020 at 6:12 am
Novartis aims to boost its respiratory treatment portfolio with a $50 million deal for an off-the-shelf cell therapy from Mesoblast that it hopes to deploy for COVID-19 patients as ...
via Bing News